Page last updated: 2024-12-09
andrimid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
andrimid: a peptide antibiotic; an anti-Bacillus compound in the marine sponge, Hyatella sp. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 636857 |
| CHEMBL ID | 425874 |
| SCHEMBL ID | 3679336 |
| MeSH ID | M0233133 |
Synonyms (5)
| Synonym |
|---|
| 108868-95-7 |
| andrimid |
| CHEMBL425874 |
| (2e,4e,6e)-n-[(1s)-3-[[(2s)-3-methyl-1-[(3r,4s)-4-methyl-2,5-dioxopyrrolidin-3-yl]-1-oxobutan-2-yl]amino]-3-oxo-1-phenylpropyl]octa-2,4,6-trienamide |
| SCHEMBL3679336 |
Research Excerpts
Overview
Andrimid is reported to be a novel kind of polyketide-nonribosomal peptide hybrid product (PK-NRPs) that inhibits fatty acid biosynthesis in bacteria. Andrimid blocks the carboxyl-transfer reaction of bacterial acetyl-CoACarboxylase.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Andrimid is reported to be a novel kind of polyketide-nonribosomal peptide hybrid product (PK-NRPs) that inhibits fatty acid biosynthesis in bacteria. " | ( Improved production of andrimid in Erwinia persicina BST187 strain by fermentation optimization. Cheng, T; Ge, T; Hou, Y; Xia, J; Zhao, L, 2023) | 2.66 |
| "Andrimid is a hybrid nonribosomal peptide-polyketide antibiotic that blocks the carboxyl-transfer reaction of bacterial acetyl-CoA carboxylase (ACC) and thereby inhibits fatty acid biosynthesis with submicromolar potency. " | ( Andrimid producers encode an acetyl-CoA carboxyltransferase subunit resistant to the action of the antibiotic. Fortin, PD; Liu, X; Walsh, CT, 2008) | 3.23 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID247897 | Inhibitory concentration of the compound against Staphylococcus aureus was determined | 2005 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4 | Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action. |
| AID245202 | Minimum inhibitory concentration against Streptococcus pneumoniae G9A strain was determined | 2005 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4 | Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action. |
| AID245102 | Minimum inhibitory concentration of the compound against Staphylococcus aureus 133 strain was determined | 2005 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4 | Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action. |
| AID245089 | Minimum inhibitory concentration of the compound againstEscherichia coli Neumann strainwas determined | 2005 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4 | Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action. |
| AID245074 | Minimum inhibitory concentration of the compound againstEscherichia coli HN818 strain was determined | 2005 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4 | Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action. |
| AID247792 | Inhibitory concentration of the compound against Escherichia coli was determined | 2005 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4 | Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (19)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 22.58
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.58) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||